United Therapeutics counsel sells 8,300 shares
United Therapeutics Corp executive Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share, then sold 8,300 shares in several trades on August 6, 2026, at weighted‑average prices per share including $512.9174 and $521.4972.
Rhea-AI Filing Summary
United Therapeutics Corp executive Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share, then sold 8,300 shares in several trades on August 6, 2026, at weighted‑average prices per share including $512.9174 and $521.4972. After the exercise he held 72,440 stock options. The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered into on August 11, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,300 shares ($3.08M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.29M)
Approx. gross sale proceeds
$4.29M
Approx. exercise cost
$1.21M
Approx. pre-tax spread
$3.08M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1 | 8,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock F1, F2 | 760 | $512.9174 | $390K |
| Sale | Common Stock F1, F3 | 1,795 | $514.8223 | $924K |
| Sale | Common Stock F1, F4 | 1,360 | $515.9303 | $702K |
| Sale | Common Stock F1, F5 | 1,617 | $516.9257 | $836K |
| Sale | Common Stock F1, F6 | 780 | $517.9411 | $404K |
| Sale | Common Stock F1, F7 | 360 | $518.8231 | $187K |
| Sale | Common Stock F1, F8 | 1,308 | $521.4972 | $682K |
| Sale | Common Stock F1 | 320 | $522.395 | $167K |
Holdings After Transaction:
Stock Option — 72,440 contracts (Direct);
Common Stock — 45,172 shares (Direct)
Footnotes (8)
- F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $512.67 to $513.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $514.47 to $515.335. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $515.50 to $516.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $516.52 to $517.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $517.53 to $518.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $518.735 to $519.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $520.91 to $521.735. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 8,300 shares
Exercise price: $146.03 per share
Shares sold: 8,300 shares
+2 more
5 metrics
Options exercised
8,300 shares
Stock options converted into common stock on August 6, 2026
Exercise price
$146.03 per share
Exercise price of stock options exercised by Paul A. Mahon
Shares sold
8,300 shares
Total common shares sold in several transactions on August 6, 2026
Example sale price
$512.9174 per share
Weighted‑average price for one reported sale block of 760 shares
Options held after exercise
72,440 stock options
Stock options reported as held following the option exercise
Key Terms
Rule 10b5-1 plan, weighted average price, stock options, derivative security
4 terms
Rule 10b5-1 plan financial
"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Paul A. Mahon report in his latest UTHR Form 4 filing?
Paul A. Mahon reported exercising 8,300 United Therapeutics stock options at $146.03 per share and selling 8,300 common shares in multiple trades on August 6, 2026, with weighted‑average per‑share prices disclosed for each trade block.
How many United Therapeutics (UTHR) options did Mahon exercise and at what price?
Mahon exercised 8,300 United Therapeutics stock options at an exercise price of $146.03 per share. These options converted into 8,300 shares of common stock, which were then reported as sold in the same Form 4 filing.
Were Mahon’s UTHR transactions made under a Rule 10b5-1 plan?
Yes. A footnote states the option exercise and sale of resulting United Therapeutics shares were made under a pre‑arranged Rule 10b5‑1 plan that Paul A. Mahon entered into on August 11, 2025.
How many United Therapeutics stock options does Mahon hold after these transactions?
Following the reported option exercise, Mahon is shown holding 72,440 United Therapeutics stock options. This post‑transaction balance comes from the line item reporting total stock options following the derivative transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
